logo
Plus   Neg
Share
Email

GTx Shares Up 26% On Enobosarm's Positive Results To Treat Urinary Incontinence

Shares of GTx Inc. (GTXI) is currently up 26% on the Nasdaq after the company Monday reported additional positive results from a phase 2 trial of its drug for postmenopausal women with stress urinary incontinence.

Memphis, Tennessee-based Gtx released additional results from a Phase 2 proof-of-concept clinical trial of 3 mg enobosarm administered orally in postmenopausal women with stress urinary incontinence, including magnetic resonance imaging results from patients' pelvic floor muscle.

The new data also suggests a positive treatment effect of enobosarm for urge incontinence suggesting a possible treatment effect for women with mixed incontinence.

Results from a pre-specified analysis of MRI data demonstrate a statistically significant increase in pelvic floor muscle thickness and urethral muscle diameter after enobosarm treatment. Treatment with enobosarm also reduced mean urge incontinence episodes by approximately 68 percent in patients who experienced urge incontinence as well as stress urge incontinence.

"Enobosarm's overall treatment effect was consistent with previously announced results, and importantly, these new results demonstrate that enobosarm may address a broader treatment need since many women suffer from symptoms of both stress and urge incontinence, also known as mixed incontinence," said Kenneth Peters, M.D., Chairman of Urology, Oakland University William Beaumont School of Medicine, and the principal investigator in the trial.

"In addition, with the MRI results, we are seeing anatomical changes supporting enobosarm's mechanism of action on pelvic floor muscle."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
After failing to sustain an early move to the upside, stocks continued to experience substantial volatility over the course of the trading day on Tuesday. The major averages fluctuated wildly as the day progressed before closing in positive territory. Despite losing to Democratic Senator-elect Kyrsten Sinema, D-Ariz., in last month's election, Congresswoman Martha McSally, R-Ariz., is still headed to the Senate next year. Former National Security Advisor Michael Flynn's closely watched sentencing on charges of lying to the FBI was unexpectedly delayed on Tuesday. U.S. District Court Judge Emmet Sullivan delayed Flynn's sentencing until the retired Army lieutenant general is done cooperating with special counsel Robert Mueller's investigation.
Follow RTT